SANA · Sana Biotechnology, Inc.
$2.75
+0.00 (+0.00%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$881.62M
Shares
299.36M
Volume · Oct 7
4.32M
Avg daily vol (3M)
3.1M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.75
Open$2.94
Day$2.74–2.98
52W close$2.68–5.92
Avg vol 30d3.7M
Short int41.4M · 13.8% float · 12.2d
Short vol55%
Last earningsMay 8, 2025
DataFeb 2021–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
call held May 8, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$211.82M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$160.49M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+24.0%
Year over year · more shares
Price change (1Y)
-33.9%
Trailing year
Short interest
13.8%
Latest settlement · 12.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−19%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−20%
trailing
YTD return
−32%
this year
Relative strength
−31%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.82% of float · ▼ -0.5% MoM · 12.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
214 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
EPS growth
+17%
Y/Y
Free cash flow
$-144.8M
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 8, 2023
Cash position / cash runway
· last into 2025
$355M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−19%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.82% of float · ▼ -0.5% MoM · 12.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
214 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 2%
Range high $6
vs 200-day avg -23%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Net Loss non-GAAP | $78.5M | six months ended June 30, 2026 | — |
| Non-GAAP operating cash burn non-GAAP | $69.3M | six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SANA
this stock
Sana Biotechnology, Inc.
|
$881.62M | -32.4% | — | — | 13.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +10.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.3% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +535.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SANA | -5.5% | -20.3% | -20.1% | -5.7% | -32.4% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -7.5% | -22.0% | -31.4% | -7.8% | -46.7% |